Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01658150 · ClinicalTrials.gov registry record · NA
Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT01658150 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 11 participants.
The verdict
NCT01658150, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.
Interventions
- DRUG isradipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-09 |
| Est. Completion | 2018-01-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01658150
The ClinicalTrials.gov registry entry for NCT01658150 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which isradipine is the first listed.
NCT01658150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01658150 about?
NCT01658150 is a clinical study titled "Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder". The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.
What is the current status of trial NCT01658150?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2012-09. Estimated completion is 2018-01-02.
What interventions are being tested in trial NCT01658150?
The interventions under investigation include: isradipine (DRUG).
Who is sponsoring clinical trial NCT01658150?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.